[1] Nieuwlaat R et al (2020) Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies. Clin. Infect. Dis. doi: 10.1093/cid/ciaa773.
[2] O ’ Neill J (2014) Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations The Review on Antimicrobial Resistance Chaired no. December, 2014.
[3] Ahmad M, Khan AU. Global economic impact of antibiotic resistance: A review. J Glob Antimicrob Resist. 2019 Dec;19:313-316. doi: 10.1016/j.jgar.2019.05.024. Epub 2019 Jun 5. PMID: 31176071.
[4] Sher L. The impact of the COVID-19 pandemic on suicide rates. QJM. 2020 Oct 1;113(10):707-712. doi: 10.1093/qjmed/hcaa202. PMID: 32539153; PMCID: PMC7313777.
[5] WHO. (OMS), COVID-19 Weekly Epidemiological Update no. November, p. 1;4, 2020, [Online]. Available: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf
[6] Zhang H, Zhang Y, Wu J et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):1958-1964. doi: 10.1080/22221751.2020.1812437. PMID: 32815458.
[7] Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Front Microbiol. 2017 Jun 23;8:1041. doi: 10.3389/fmicb.2017.01041. PMID: 28690590; PMCID: PMC5481322.
[8] Liderot K, Ahl M, Ozenci V. Secondary bacterial infections in patients with seasonal influenza A and pandemic H1N1. Biomed Res Int. 2013;2013:376219. doi: 10.1155/2013/376219. Epub 2013 Jun 20. PMID: 23865050; PMCID: PMC3705841.
[9] Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12. PMID: 32294485; PMCID: PMC7152876.
[10] Li J et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrobial Resistance and Infection Control (2020) 9:153. doi: 10.1186/s13756-020-00819-1.
[11] Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;: PMID: 31986264; PMCID: PMC7159299.
[12] Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.
[13] Yang X et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 05; 8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5.
[14] RotheK, Feihl S, Schneider J et al. (2020) Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-020-04063-8.
[15] Sivapalan P, Ulrik CS, Bojesen RD et al. (2020) Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 21(1):513. doi: 10.1186/s13063-020-04409-9..
[16] Metin N, Turan Ç, Utlu Z. (2020) Changes in dermatological complaints among healthcare professionals during the COVID-19 outbreak in Turkey. Acta Dermatovenerol Alp Pannonica Adriat. 29(3):115-122. PMID: 32975297.
[17] Tiri B, Sensi E, Marsiliani V, et al. (2020) Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work?. J Clin Med. 2020;9(9):2744. doi:10.3390/jcm9092744
[18] Rochtus A, Izzi B, Vangeel E, et al. (2015) DNA methylation analysis of Homeobox genes implicates HOXB7 hypomethylation as risk factor for neural tube defects. Epigenetics. 2015;10(1):92-101. doi:10.1080/15592294.2014.998531
[19] Morens DM, Taubenberger JK, Fauci AS. (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-970. doi:10.1086/591708
[20] The Republic of Turkey Ministry of Health, ‘COVID-19 (SARS-COV-2 Infection) (Study of Scientific Board) General Information, Epidemiology and Diagnosis’, vol. 19, no. May, pp. 1–21, 2020.
[21] ‘The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0’, 2019. http://www.eucast.org.
[22] Rice TW, Rubinson L, Uyeki TM et al., (2012) NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012 May;40(5):1487-98. doi: 10.1097/CCM.0b013e3182416f23.
[23] Yap FH, Gomersall CD, Fung KS et al. (2004) Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis. 2004 Aug 15;39(4):511-6. doi: 10.1086/422641.
[24] He F, Xia X, Nie D et al. (2020) Respiratory bacterial pathogen spectrum among COVID-19 infected and non-COVID-19 virus infected pneumonia patients. Diagn Microbiol Infect Dis. 2020 Dec;98(4):115199. doi: 10.1016/j.diagmicrobio.2020.115199.
[25] Vazzana N, Dipaola F, Ognibene S. (2020) Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. Acta Clin Belg. 2020 Sep 23:1-5. doi: 10.1080/17843286.2020.1824749.
[26] Langford BJ, So M, Raybardhan S et al. (2020) Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016.
[27] Kodaz H. (2020) Successful Treatment Strategy of Turkey against Covid-19 Outbreak. Eurasian J. Med. Oncol., 2020, doi: 10.14744/ejmo.2020.12345.
[28] Ramadan HK, Mahmoud MA, Aburahma MZ et al. (2020) Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt. Infect Drug Resist. 2020 Oct 5;13:3409-3422. doi: 10.2147/IDR.S272605.
[29] Perez S et al. (2020) Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions — New Jersey, February–July 2020. MMWR. Morb. Mortal. Wkly. Rep., vol. 69, no. 48, p. 1827, Dec. 2020, doi: 10.15585/mmwr.mm6948e1.